Because PDE4 determines several inflammatory pathways in psoriasis [21], we hypothesized that inhibition of PDE4 by apremilast would result in a greater improvement of endothelial glycocalyx integrity, vascular and LV myocardial function compared with TNF-α inhibitor or cyclosporine treatment. This evidence concerns the gene PDE4A and psoriasis.